John Newman
Stock Analyst at Canaccord Genuity
(2.10)
# 2,869
Out of 4,896 analysts
81
Total ratings
46.48%
Success rate
-9.02%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,152 → $850 | $567.74 | +49.72% | 16 | Apr 22, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.28 | +993.75% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $112.96 | +51.77% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $9.19 | +84.98% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.71 | +367.84% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $5.81 | +330.29% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $12.57 | +1,491.09% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $11.34 | +85.19% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $68.92 | +66.86% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.75 | +967.38% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $54.54 | +22.85% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $13.12 | +227.74% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.18 | +323.73% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $39.06 | +12.65% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $9.27 | +2,273.25% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $16.04 | +136.91% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $4.65 | +480.65% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $8.80 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Apr 22, 2025
Maintains: Buy
Price Target: $1,152 → $850
Current: $567.74
Upside: +49.72%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.28
Upside: +993.75%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $112.96
Upside: +51.77%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $9.19
Upside: +84.98%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.71
Upside: +367.84%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.81
Upside: +330.29%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $12.57
Upside: +1,491.09%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $11.34
Upside: +85.19%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $68.92
Upside: +66.86%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.75
Upside: +967.38%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $54.54
Upside: +22.85%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $13.12
Upside: +227.74%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.18
Upside: +323.73%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $39.06
Upside: +12.65%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $9.27
Upside: +2,273.25%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $16.04
Upside: +136.91%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $4.65
Upside: +480.65%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $8.80
Upside: -